Refining Alzheimer's disease biological diagnosis with plasma biomarkers: Resolving p‐tau217 “gray zone” with p‐tau181 integration

Abstract BACKGROUND Blood‐based biomarkers offer a less invasive and more scalable alternative to cerebrospinal fluid (CSF) analysis and amyloid‐positron emission tomography (PET) for the biological diagnosis of Alzheimer's disease (AD). Among blood‐based biomarkers (BBMs), plasma phosphorylated tau...

Полное описание

Библиографические подробности

Главные авторы:	Giulia Giacomucci, Silvia Maria Rita Tabbì, Assunta Ingannato, Silvia Bagnoli, Sonia Padiglioni, Chiara Crucitti, Chiara Sensi, Serena Sanesi, Valentina Moschini, Carmen Morinelli, Giulia Galdo, Valentina Berti, Benedetta Nacmias, Valentina Bessi
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Wiley 2026-01-01
Серии:	Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Предметы:	Alzheimer's disease mild cognitive impairment plasma biomarkers plasma GFAP plasma NfL plasma p‐tau181
Online-ссылка:	https://doi.org/10.1002/dad2.70285
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!